Table 1.
Participant characteristics among adults in selected antiretroviral treatment programs in Tanzania, Uganda and Zambia, 2011.
| Characteristic | Tanzania (n=1498) |
Uganda (n=1495) |
Zambia (n=1496) |
Total number of participants (N=4489) |
Sample from sites with VL measurements (n=1497) |
|---|---|---|---|---|---|
| Demographics | |||||
| Age (years) median (IQR) | 41 (35–47) | 39 (34–46) | 40 (34–47) | 40 (34–47) | 39 (33–46) |
| Age: n (%) | |||||
| <35 years | 350 (23.4) | 406 (27.2) | 395 (26.4) | 1151 (25.6) | 443 (29.6)* |
| ≥35 years | 1133 (75.6) | 1028 (68.8) | 1093 (73.1) | 3254 (72.5) | 1029 (68.7) |
| Missing | 15 (1.0) | 61 (4.1) | 8 (0.5) | 84 (1.9) | 25 (1.7) |
| Sex: n (%) | |||||
| Female | 1096 (73.2) | 982 (65.6) | 968 (64.7) | 3045 (67.8) | 999 (66.7) |
| Male | 402 (26.8) | 514 (34.4) | 528 (35.3) | 1444 (32.2) | 498 (33.3) |
| Marital status: n (%) | |||||
| Single | 204 (13.6) | 116 (7.8) | 122 (8.2) | 442 (9.8) | 149 (9.95) |
| Separate/divorced/widowed | 425 (28.4) | 637 (42.6) | 476 (31.8) | 1538 (34.3) | 496 (33.1) |
| Married/cohabitating | 863 (57.6) | 734 (49.1) | 898 (60.0) | 2495 (55.6) | 850 (56.8) |
| Missing | 6 (0.4) | 8 (0.5) | 0 (0.0) | 14 (0.3) | 2 (0.1) |
| ART characteristics | |||||
| Length of time on ART: n (%) | |||||
| <2.2 years | 425 (28.4) | 373 (24.9) | 304 (20.3) | 1102 (24.5) | 316 (21.1)* |
| 2.2–5.3 years | 739 (52.9) | 735 (49.2) | 721 (48.2) | 2249 (50.1) | 774 (51.7) |
| >5.3 years | 280 (18.7) | 387 (25.9) | 471 (31.5) | 1138 (25.4) | 407 (27.2) |
| Current ART regimen: n (%) | |||||
| D4T, 3TC, NVP | 561 (37.4) | 11 (0.7) | 159 (10.6) | 731 (16.3) | 321 (21.4)* |
| TDF, 3TC/FTC, EFV | 116 (7.7) | 86 (5.8) | 498 (33.3) | 700 (15.6) | 263 (17.5) |
| ZDV, 3TC, EFV | 396 (26.4) | 300 (20.1) | 78 (5.2) | 774 (17.2) | 271 (18.1) |
| ZDV, 3TC, NVP | 262 (17.5) | 909 (60.8) | 256 (17.1) | 1427 (31.8) | 418 (27.9) |
| Other regimens | 70 (4.7) | 175 (11.7) | 437 (29.2) | 682 (15.2) | 198 (13.2) |
| Missing | 93 (6.2) | 14 (0.9) | 68 (4.5) | 175 (3.9) | 26 (1.7) |
| CD4+ cell count prior to ART: n (%) | |||||
| >250 cells/μl | 213 (14.2) | 111 (7.4) | 243 (16.2) | 567 (12.6) | 198 (13.2) |
| ≤250 cells/μl | 995 (66.4) | 1087 (72.7) | 938 (62.7) | 3020 (67.3) | 989 (66.1) |
| Missing | 290 (19.4) | 297 (19.9) | 315 (21.1) | 902 (20.1) | 310 (20.7) |
3TC, lamivudine; D4T, stavudine; EFV, efavirenz; FTC, emtricitabine; IQR, interquartile range; NVP, nevirapine; TDF, tenofovir; VL, viral load; ZDV, zidovudine.
*
P<0.05 comparing the subset of participants from VL testing sites to the total study sample.